Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00140361
Status:
COMPLETED
Last Update Posted:
2012-09-11
First Post:
2005-08-30
Brief Title:
Efficacy of Sulphadoxine-pyrimethamine and Artemisinin-containing Combination Therapy for Malaria
Sponsor:
Centers for Disease Control and Prevention
Organization:
Centers for Disease Control and Prevention
Study Overview
Official Title:
Assessing and Monitoring the Efficacy of Sulfadoxine Pyrimethamine SP and the Combination of SP Plus Artesunate for Uncomplicated Malaria Infections Among Children
Status:
COMPLETED
Status Verified Date:
2012-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an ongoing monitoring activity of efficacy of sulfadoxine-pyrimethamine SP which is the current national treatment of choice for uncomplicated malaria in Tanzania and a combination of SP and artesunate among children 5 years in 3 sites in rural Tanzania
Protocol was amended in 2004 to 1 include lumefantrineartemether the newly identified first-line treatment for malaria to be introduced into Tanzania in 2006 2 on a limited basis include adult patients 3 extend follow-up to 28 days 4 investigate whether treated bednets would reduce confounding by reinfection
Protocol was amended in 2004 to 1 include lumefantrineartemether the newly identified first-line treatment for malaria to be introduced into Tanzania in 2006 2 on a limited basis include adult patients 3 extend follow-up to 28 days 4 investigate whether treated bednets would reduce confounding by reinfection
Detailed Description:
This is an ongoing monitoring activity of efficacy of sulfadoxine-pyrimethamine SP which is the current national treatment of choice for uncomplicated malaria in Tanzania and a combination of SP and artesunate among children 5 years in 3 sites in rural Tanzania
Protocol was amended in 2004 to 1 include lumefantrineartemether the newly identified first-line treatment for malaria to be introduced into Tanzania in 2006 2 on a limited basis include adult patients 3 extend follow-up to 28 days 4 investigate whether treated bednets would reduce confounding by reinfection
Protocol was amended in 2004 to 1 include lumefantrineartemether the newly identified first-line treatment for malaria to be introduced into Tanzania in 2006 2 on a limited basis include adult patients 3 extend follow-up to 28 days 4 investigate whether treated bednets would reduce confounding by reinfection
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| UR3CCU018969-01 | None | None | None |